SELECT-GCA Trial results show UPA 15 mg + 26-week GC taper leads to 46% sustained remission vs. 29% with placebo + 52-we
Tweet Content
SELECT-GCA Trial results show UPA 15 mg + 26-week GC taper leads to 46% sustained remission vs. 29% with placebo + 52-week taper (P=.0019).
UPA15 reduced GC use (median 1615mg vs. 2882mg, P<.0001) and improved fatigue scores.
Key finding: UPA15 combined with a 26-week GC… https://t.co/rdHU3GuOwc https://t.co/oMS7x46sIB
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off